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THE ROLE OF FECAL MIROBIOTA TRANSPLANTS IN THE MANAGEMENT 
OF INFLAMMATORY BOWEL DISEASE 
SEJAL MAHESH THAKER 
ABSTRACT 
 Recent advances have increased the understanding that dysbiosis of the gut 
microbiome may be a significant contributor to the pathophysiology of ulcerative colitis. 
Because of this, the use of fecal microbiota transplants (FMT) has become more popular 
as a potential supplemental treatment option for patients suffering from this disease. 
Research has shown a possible benefit of FMT in conjunction with varying conventional 
therapies for patients with mild to moderate disease severity. However, there are scarce 
publications that have investigated the benefit of FMT in conjunction with a single 
conventional therapy for patients with moderate to severe disease, specifically. The 
proposed study is a multicenter, double blind, randomized controlled study of FMT, 
mercaptopurine (6-MP), and prednisone vs 6-MP and prednisone alone in patients with 
moderate to severe ulcerative colitis. The study subjects will have a baseline evaluation 
and the treatment trial will last 8 weeks with follow up throughout the study. 
Investigators will analyze the primary outcome of clinical remission and secondary 
outcomes of improvement of fecal calprotectin levels, Inflammatory Bowel Disease 
Questionnaire (IBDQ) score, C-reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR) in the treatment vs control groups. The data from this study will help to identify if 
FMT would be an additional safe, efficacious treatment modality to the current medical 
management of ulcerative colitis.  
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INTRODUCTION 
Background 
Inflammatory bowel disease (IBD) is a set of disorders characterized by chronic 
inflammation of the intestine that typically presents in the second to forth decade of life1. 
The two major types of IBD are Crohn’s disease and ulcerative colitis (UC), which can 
be differentiated based on physical exam, endoscopic findings, anatomic distribution of 
the disease, histologic features, and potentially serologic testing. UC typically presents as 
diarrhea mixed with blood or mucous, abdominal discomfort, tenesmus, and in more 
severe situations, evidence of systemic toxicity or toxic megacolon.  Endoscopically, 
ulcerative colitis manifests as mucosal inflammation beginning in the rectum and 
extending proximally in a continuous fashion. Endoscopic classification is based partly 
on the extent of involvement. A combination of clinical features and endoscopic scoring 
is used to classify UC into mild, moderate, and severe disease, usually via the Mayo 
Score2.  
In the United States, the incidence of UC is estimated to be 9-12/100,000 cases, 
with prevalence estimated to be 205-240/100,000 individuals2. Genetic, environmental, 
bacterial and immunologic factors have been implicated as causal risk factors for UC, but 
there are still many unknowns regarding the etiology and management of this condition. 
Diet, oral contraceptives, and infections have been suggested to play a role in the 
development of UC, but none of these associations have been proven3. Despite extensive 
research efforts, UC is a lifelong illness that is currently incurable with pharmacological 
treatment alone. The goals of therapy are directed towards inducing and maintaining 
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remission, preventing complications, optimizing the need for surgical intervention and 
improving quality of life4. Medical treatments of UC focus on modulating or suppressing 
the immune system given the inflammatory nature of the disease. A combination of 
aminosalicylates (5-ASA), corticosteroids, immune modulators (6MP, azathioprine, 
methotrexate), biologic medications (infliximab, adalimumab, golimumab, natalizumab, 
and vedolizumab), and surgery are used as treatment methods depending on severity of 
the disease2. Surgery is generally reserved for patients who are either refractory to 
medical management or who experience severe complications such as bowel perforation, 
hemorrhage, fulminant disease, a high suspicion of cancer, or systemic complications. In 
these situations, total colectomy is generally considered curative for patients with 
ulcerative colitis. 
Efforts to develop future treatments for UC have identified several potential 
targets of intervention. Some research has focused on dysfunction of the intestinal barrier 
and dysregulation of the immune system5. However, evidence also  shows that gut 
microbial flora significantly contribute to the metabolic, immunologic and homeostatic 
properties of the intestine6. Studies have shown that an imbalance in intestinal 
microbiota, known as dysbiosis, may play a role in the pathogenesis of ulcerative colitis7. 
This has catalyzed further investigation and identification of  the organisms which reside 
in the gut to understand the interactions between the intestinal immune system and the 
microbes8. Manipulation of the intestinal microbiota has been suggested as a possible 
therapeutic intervention for UC.  
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One method of modulating the gut microbiome is through the use of fecal 
microbiota transplants (FMT). The mechanism of action of FMT is believed to be the 
restoration of natural intestinal flora through the introduction of beneficial new species 
from the donor while also supplementing other species present at low populations in the 
host6. FMT was first used as an oral suspension in China during the 4th century to treat 
food poisoning6. Formal known use of this modality in humans did not resurface again 
until the mid-1900s when it was documented to be effective in a trial to treat children 
with pseudomembranous colitis6. In 1983, the first case of using FMT to treat 
Clostridium difficile infection (CDI) was confirmed, and since then, there has been 
increasing interest in the study and use of this therapy with promising results for recurrent 
CDI6. In fact, FMT is now included in clinical practice guidelines developed by the 
American College of Gastroenterology (ACG) for recurrent or relapsing CDI, moderate 
CDI that does not respond to standard therapy for a week, or severe CDI with no 
improvement with therapy over a period of 48 hours6.  
Statement of the Problem 
Use of FMT has recently been increasing given that clinical trials have proven it to be 
effective in treating patients suffering from recurrent, antibiotic resistant Clostridium 
difficile infections9.  This has prompted studies to evaluate the efficacy of FMT as a 
remission inducing therapy for individuals suffering from other intestinal disorders such 
as UC. The largest study of to datefound that 24% of UC patients who received FMT 
were able to achieve remission compared to 5% in the placebo group (p<0.05)10. 
However, this study, similar to many others, allowed patients to continue using their 
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individualized conventional therapies while receiving FMT, resulting in variations among 
treatment regimens. Additionally, the majority of studies that have investigated the use of 
FMT in UC patients have only included individuals who suffer from mild to moderate 
disease severity. There are few studies that have used a single conventional therapy 
coupled with FMT to evaluate its efficacy as an adjuvant agent in inducing remission in 
patients with moderate to severe ulcerative colitis.  
Hypothesis 
Fecal microbiota transplants used in conjunction with 6-mercaptopurine (6-MP) and 
prednisone will have higher rates of remission for ulcerative colitis in patients with 
moderate to severe disease previously unresponsive to 5-ASA therapy compared to 6-
mercaptopurine and prednisone alone. 
Objectives and specific aims 
Based on the theory that microbial flora contribute to the pathogenesis of ulcerative 
colitis, the objective of this study is to identify if manipulation of intestinal microbiome 
can be used to treat ulcerative colitis. Specific aims include: 
 To determine if FMT is an effective adjuvant treatment to 6-MP and 
corticosteroids to induce remission in patients with moderate to severe ulcerative 
colitis 
 To determine if FMT, 6-MP and corticosteroids can improve inflammatory 
biomarkers in patients with moderate to severe UC from baseline 
 To determine if FMT, 6-MP and corticosteroids can improve quality of life 
measures based on IBDQ score in patients with moderate to severe UC 
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 To help identify where FMT should lie in the traditional treatment algorithms for 
UC 
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REVIEW OF THE LITERATURE 
Overview 
Ulcerative colitis is diagnosed based on a combination of clinical findings, including 
patient symptoms, laboratory markers, endoscopic findings, and histology. The onset of 
UC is gradual and it can progress over time for several weeks. The most common signs 
and symptoms of ulcerative colitis include cramping abdominal pain, fever, weight loss, 
and increase in urgency and frequency of defecation with bleeding and passage of mucus 
in stool3. Inflammatory markers, which are elevated in the majority of patients with 
active UC, such as fecal calprotectin, erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) are commonly monitored to identify disease activity. On 
endoscopy, notable findings can include mucosal inflammation with erythema, 
granularity, friability with bleeding, loss of vascular markings, and/or ulceration of the 
large intestine, progressing from the rectum to the cecum in a continuous fashion. 
Endoscopic findings can include loss of vascular marking due to edematous mucosa, 
erythematous appearing mucosa with increased granularity, exudates, erosions, and 
friability. Because the endoscopic findings can be nonspecific, biopsies of the colon are 
necessary to demonstrate chronicity of inflammation and exclude other causes of colitis.  
The most common locations of involvement are the rectum and distal colon because of 
the contiguous spreading of the disease.  Histology of ulcerative colitis reveals 
inflammation of the inner mucosal lining with crypt abscesses and architectural 
distortion3. Additionally, ulcerative colitis can be associated with to a variety of 
extraintestinal manifestations that involve the eyes, hepatobiliary system, skin, and most 
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commonly the joints11. Ulcerative colitis can result in potential complications such as 
gastrointestinal hemorrhage, bowel perforation, toxic megacolon, and colorectal 
carcinoma. 
The pathophysiology of UC is poorly understood; however, studies continue to 
explore several theories. Among these includes a theory regarding dysregulation of the 
patient’s immune system towards either normal or dysbiotic commensal bacteria5. The 
large number of microbes that inhabit the intestine result in continuous interaction 
between the host cells and bacteria, and the intestinal immune system must carefully 
balance defense against pathogens and tolerance of symbiotic bacteria. Disruption of host 
tolerance to non-pathogenic resident bacteria is believed to predispose individuals to 
ulcerative colitis, and in fact, there have been observations of increased levels of 
antibodies directed against intestinal bacteria in the mucosa of patient’s with IBD5,12. 
Additional investigations have identified specific inflammatory cells and cytokines 
believed to play a central role in the induction and persistence of ulcerative colitis 13. 
Such studies have influenced the development of medical therapies aimed to decrease 
intestinal inflammation and modulate host immune responses. 
 There are a multitude of medical agents aimed at immune responses which are 
used to improve quality of life, induce remission and prevent relapse in individuals with 
UC. Current therapies are individualized to each patient based on location, extent and 
severity of disease. A step-up approach for medical therapy has been used to effectively 
treat patients14. The medications traditionally used include 5-aminosalicyc acid (5-ASA), 
corticosteroids, immune modulators, and biologics2.  
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5-ASA agents are among the first to be used to manage UC. They are available 
for administration through oral forms and topical methods. The exact mechanism of 
action is unclear but they are believed to act in an anti-inflammatory fashion. Studies 
have shown that this agent improves symptoms within 2-4 weeks of initiating treatment, 
and they are effective for inducing remission in mild-to-moderately-active UC2. This 
makes it the first medication of choice in the step up approach for patients with this 
disease severity. Additionally, studies have proven that continuing 5-ASA therapy while 
in remission aids in the prevention of relapse2. Randomized controlled trials have shown 
that adverse effects are not increased compared to placebo although rare adverse events 
such as interstitial nephritis, pancreatitis, pericarditis and hepatitis have been 
documented2.  
 Corticosteroids are anti-inflammatory agents typically reserved for acute UC 
flares. This medication can be administered orally, parenterally, and topically. The 
molecules interact with glucocorticoid receptors, resulting in an inhibitory effect2. This 
reduces the expression of adhesion molecules and the attraction of inflammatory cells to 
a specific site. Additionally, corticosteroids diminish the expression of inflammatory 
cytokines and stimulate cell death of lymphocytes2. Randomized controlled trials have 
shown that corticosteroids are effective at inducing remission in active UC2. However, 
because this medication can be involved in a large amount of physiological processes, it 
is associated with a variety of adverse effects including increased risk of infection, 
psychiatric illnesses, Cushing’s disease, hyperglycemia, and osteoporosis. Therefore, the 
risks make this an undesirable long term therapy, and its use is primarily reserved for 
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inducing remission rather than maintenance.  As such, patients requiring corticosteroids 
to induce a remission must also be started on another medical agent to help maintain the 
remission. 
 The next level of the step-up approach includes the immune modulating therapies 
6-mercaptopurine (6-MP), azathioprine (AZA), and methotrexate which work to alter the 
number or function of immune cells2. These are used for patients who do not respond to 
5-ASA agents or for those with moderate-severe disease severity2. Studies have shown 
that AZA and 6-MP are more effective than placebo for maintenance of remission, but 
most evidence shows no statistically significant benefit of AZA/6-MP as an induction 
agent15,16. This may be because ASA/6-MP require 3-6 months of administration before 
they are effective. Therefore, these medications are often started with corticosteroids or 
biologic agents (which can induce remission) during acute flares to serve as an eventual 
maintenance regimen.    
 The final layer of the step-up approach includes the biologic agents which are 
monoclonal antibodies targeted against tumor necrosis factor alpha and integrin, key 
components of the immune activity in UC. Medications in this class currently include 
infliximab, adalimumab, golimumab, natalizumab, and vedolizumab. The ACT 1 and 
ACT 2 trials for infliximab and CHARM trial for adalimumab have showed that these 
agents are effective at inducing and maintaining remission in patients with moderate-to-
severely active UC2,17. Once remission has been achieved, life-long therapy is required in 
attempt to prevent relapse. Although effective, these medications result in varying 
degrees of immunosuppression and cause patients to be vulnerable to infectious 
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complications. Patients taking these therapies also have an increased risk of developing 
non-Hodgkins lymphoma, other malignancies and infusion reactions. Because these 
biologic therapies are presently the final pharmaceutical approach to management of UC 
before surgical intervention, it would be beneficial to determine if another medical 
therapy can be used in conjunction with standard therapies to induce remission.   
Figure 1: Traditional Step Up Treatment Approach adopted from Hanauer SB18 
  
 
 
 
 
Intestinal dysbiosis and reduced gut biodiversity biodiversity has been thought to 
contribute to the etiology of UC. Over the last 15 years, there have been advances in 
DNA sequencing that have allowed scientists to explore the 40% of microbes living in 
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in the use of culturing techniques and molecular analysis to gain further understanding of 
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Studies such as this have been important to understand that dysbiosis may 
contribute to UC; however because the microbial composition of the gut differs greatly 
between individuals depending on environmental and genetic factors, it is difficult to 
identify a single causative organism to target for therapy12. Therefore, techniques to 
modulate the gut microbiome as a whole have been explored via the use of fecal 
microbial transplants.  
FMT derives commensal bacterial from stool samples of healthy donors and 
introduces them in patients with enteric bacterial imbalances. The transplanted bacteria 
exert their therapeutic benefit by colonizing the recipient gut and outcompeting 
pathogenic bacteria for nutrients. Successful treatment for patients develops a more 
diverse population of microflora and restores gut bacteria that may have been present in 
low numbers21.   
The successful use of FMT for CDI has prompted the ACG to create guidelines 
for the selection of FMT donors 6. Laboratory tests are performed to test for specific 
pathogens in both the stool and serum of potential donors to assure that they are free of 
transmissible disease. Additionally, a portion of the exclusion criteria requires that donors 
do not have any medical history of autoimmune disorders, intrinsic GI illnesses, or 
oncologic diagnoses6.  
For effective administration, stool is homogenized in either water, milk, or normal 
saline using a mixing tool6. It is then filtered to remove large, undesirable particles and 
either infused directly into the patient, or further processed into capsules. The solution is 
administered to the patient via upper endoscopy, nasogastric tube, colonoscopy, rectal 
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tube, enema, or swallowed in the recently developed pill form. Currently, studies 
comparing the most effective method of administration are limited and there is no formal 
agreement regarding the best mode of installation.  
Studies that have identified dysbiosis as a contributing factor to the 
pathophysiology of UC suggest that FMT may be a beneficial adjuvant treatment for 
patients suffering from acute disease flairs. Addressing immune dysregulation towards 
commensal bacteria and dysbiosis simultaneously may be useful to induce remission in 
patients with moderate to severe UC. This would add another potential therapy to the step 
up approach.  
Existing research 
Ongoing investigations continue to reveal that FMT may be able to correct 
dysbiosis and restore a more natural enteric microbiome. One study observed alterations 
in the structure and composition of microbiota in feces before and after using FMT to 
treat CDI22. Molecular analysis and metagenomics were used to compare the microbiota 
from the host (pre and post FMT) fecal samples to that of their respective donors22. The 
primary goal was to identify changes in the host fecal microbiome after FMT to discover 
if this modality is efficacious at restoring more natural gut colonization22. The 
investigators found that the microbiome following FMT had significant changes with 
restoration of diversity and structure. 22. The data suggests that the fecal microbiome of 
hosts after FMT administration more closely resemble that of each donor, highlighting 
the importance of a healthy donor22. Although the sample population of the study was 
small, it was reported that the findings are supported by observations of similar previous 
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studies 22. These research efforts are crucial to understand that FMT can be an effective 
agent to alter the gut microbiome in a favorable fashion.  
  Researchers have been using investigations of FMT for CDI as guidance to test 
the efficacy for FMT for UC. In 1989, Bennet and Brinkman were the first to report the 
use of FMT for UC23. Bennet self-administered fecal retention enemas which induced 
remission of his own UC, and 6 months after the intervention he continued to be free of 
symptoms without medications23. Shortly thereafter, another investigator published a case 
series that featured 6 patients who had diagnoses of UC for at least 5 years and had failed 
the maximum medical interventions at the time23. A combination of pretreatment 
antibiotics and 5 days of fecal retention enemas resulted in remission for all 6 patients23.  
More recently, a systematic review and meta-analysis was performed to evaluate 
studies which used FMT as a primary therapeutic agent in IBD patients. All of the studies 
included in the review allowed patients to continue their conventional medication 
regimens and defined clinical remission as the primary outcome. Subgroup meta-analysis 
the patients who suffered from UC demonstrated that about 24.1% of the patients who 
received FMT in conjunction with individual conventional therapies achieved clinical 
remission and there was a low risk for heterogeneity 24. The study provided a 
comprehensive overview of the treatment success of FMT as an adjuvant for inducing 
remission in UC patients but was limited by publication bias due to the inclusion of case 
studies in the analysis24. Additionally, the review was limited by the small number 
patients and lack of controlled trials, highlighting the need for more robust investigation. 
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Nonetheless, the findings suggest that altering gut microbial flora may be a promising 
treatment for UC. 
The largest randomized controlled trial for FMT in any disease has shown the 
potential of FMT to be an effective treatment option in patients with UC. In the study, 
FMT or water was administered via sigmoidoscopy and retention enema once a week for 
6 weeks and the primary outcome was remission at week 7. Patients taking concomitant 
treatments were permitted to continue these throughout the trial as long as the doses were 
stable for a specified time period. The trial resulted in statistically significant findings 
with 24% of the participants in the FMT group achieving remission at the end of the 
experiment compared to 5% in the placebo group10. The remission rate of 24% was 
notably similar to the remission rate found in the subgroup meta-analysis performed by 
Coleman and Rubin (24.1%). The study however did not target patients with a specific 
disease severity. Although the mean Mayo score of the patients who received FMT was 
calculated, there was no analysis comparing FMT remission and response rates of 
patients with mild to moderate disease vs. those with moderate to severe disease. More 
randomized controlled trials such as this are necessary to further reveal the benefit of 
FMT in UC patients.  
Managing UC from two contributing processes simultaneously may be more 
effective that targeting them individually. Maoyyedi et al. showed trends towards 
individuals taking immunosuppressant agents to have an increased benefit from FMT 
compared to those not on immunosuppressant therapy10. At 12 month follow up, 8 of 9 of 
the patients that received FMT and achieved remission remained in remission 10. These 
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findings support the idea that combination therapy of FMT with conventional 
immunosuppressive therapies may be beneficial to induce remission in patients with UC 
compared to FMT alone.  
Beneficial changes of the intestinal microbiota after FMT have been reported in 
patients with UC. In randomized controlled trials, analysis of the microbiome outcomes 
showed that there was more diversity and statistically significant changes in the 
composition of the microbiota in the treatment groups vs. the placebo groups 10,25. The 
investigators of these trials identified that the microbiota of individuals who responded to 
the FMT was distinct from that of the nonresponders25.  Interestingly in one of the 
studies, the majority of individuals that achieved clinical remission all received FMT 
from the same donor 25. Analysis showed that responders had microbiota more similar to 
the specific donor than non-responders, but this was found to not be statistically 
significant. This suggests that response effect may be dependent on the donor and 
restoration of a more natural gut colonization may play a significant role in the 
management of UC.  
A reasonable concern regarding the use of FMT in patients with UC is the safety of 
the intervention, especially regarding patients taking immune suppressing medications. A 
prospective, open-label, uncontrolled study explored this concern after administering 
FMT to children and young adults with UC26. Administration of FMT was via retention 
enema daily for a period of 5 days and during this time, subjects continued taking their 
individualized conventional medications. Seven of the 9 subjects showed clinical 
improvement and 3 out of 9 subjects achieved clinical remission within 1 week of FMT26. 
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The majority of the adverse events were mild (see Table 1) and there were no serious 
adverse events noted26. Overall, the study found that adverse effects were manageable, 
self-limiting and acceptable to the subjects26. In addition to showing potential efficacy of 
FMT at inducing remission in patients with UC, the study also discovered it was a safe 
treatment while on other conventional medications.  
Table 1. Subject Reported Symptoms adopted from Kunde et al. 26 
Reported Symptoms Reported Severity Number of 
Subjects Overall 
Bloating/Flatulence 
Abdominal Pain 
Diarrhea 
Hematochezia 
Fatigue 
Fever 
Mild to Moderate 
Mild  
Mild to Moderate 
Mild  
Mild to Moderate 
Mild to Moderate 
9 
9 
6 
6 
3 
2 
 
More studies are indicated to evaluate the safest and most efficacious mode of 
installation; however, the current data suggests that FMT is a safe and tolerable 
intervention for patients with UC.  
Infrequent use of FMT may also be due to the assumed unappealing nature of the 
intervention. There have been a limited number of studies that have used surveys to 
evaluate the patient perception of FMT. One publication has shown that patients are 
willing to consider FMT as a therapy, and would choose the intervention if recommended 
by a physician27. The study did support the assumption that FMT is an unappealing 
treatment modality; however, survey participants have expressed willingness to accept it 
regardless of this. The findings also suggest that the support, advice and education 
provided by a healthcare provider plays an important role in the acceptance of FMT. A 
weakness of this study is that the participants were naïve of GI illnesses and therefore did 
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not provide perspective of individuals suffering from a enteric disease processes27. 
Additionally, the small sample size decreases the generalizability of the study.  
Another study aimed to identify interest in and concerns about FMT for patients 
with UC. Ninety-five participants from the University of Chicago IBD Center completed 
the survey. Interestingly, the majority of the patients reported either excellent or 
good/satisfactory medical management of their UC at the time the survey was 
administered. Even so, 46% stated they would be willing to receive FMT and 43% were 
“unsure”28.  The data shows that the vast majority of patients are willing to accept or 
willing to consider FMT despite having excellent or satisfactory medical management of 
their disease. Subgroup analysis revealed that patients who had been hospitalized for their 
UC were more willing to receive FMT, indicating that disease severity may play a role in 
decision making. Weaknesses of the study include the small sample size and that 
recruitment was from a single medical center which decreases the generalizability of the 
results28. 
Focus groups are a beneficial method to identify perceptions and interest in FMT. 
Studies have revealed that if there was careful donor screening and adequate research 
supporting the safety and efficacy of FMT, the adult patients and parents of children 
suffering from the disease would consider accepting FMT as a treatment for UC29. Most 
importantly, the study highlights that participants believed the potential benefits of FMT 
greatly outweigh the unappealing factors associated with the intervention.   
Patient interest in FMT is not the only opinion that is included in the adoption of 
this treatment method. Although there is enthusiasm for the future of FMT, the majority 
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of gastroenterologists have limited access to or experience with the intervention30. 
Studies have aimed to investigate the experience and perceptions that gastroenterologists 
have regarding FMT30. The majority of clinicians in a particular study reported that they 
had referred patients for FMT in the past and would refer their UC patients if it was 
easily available. The biggest concern reported by the gastroenterologists was lack of 
evidence regarding the efficacy of FMT for UC. Despite the minimal short term data and 
lack of long term data, the majority did not report reservations about the safety of FMT. 
This stresses the importance of amplifying research regarding the efficacy of FMT for 
UC patients.  
These preliminary studies have shown that FMT appears to be a safe, practical, 
and efficacious for the treatment of UC, likely through restoration of the gut microbiome 
to a less immunogenic state. There is also a favorable perception of FMT by patients and 
providers alike, but all agree that more data is needed to verify its benefit and clarify its 
place in existing treatment algorithms for UC. The purpose of the proposed research trial, 
below, is therefore to address these issues, limiting the study only to patients with 
moderate to severe UC who are naïve to treatment with biologic agents. 
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METHODS 
Study design 
This will be a multicenter, randomized controlled study of FMT, 6-MP and prednisone vs 
6-MP and prednisone alone in patients with moderate to severe ulcerative colitis.  
Study population and sampling 
The patients will be recruited over a period of 12 months from the outpatient 
gastroenterology clinics of 6 major academic institutions throughout Boston: Boston 
Medical Center, Brigham and Women’s Hospital, Lahey Medical Center, Tufts Medical 
Center, Beth Israel Deaconess Medical Center and Massachusetts General Hospital. 
Inclusion and exclusion criteria can be found in Table 2. Disease severity will be 
evaluated using the Mayo score which takes into consideration stool pattern, rectal 
bleeding, endoscopic findings, and global evaluation by a health care provider 31. Based 
on these factors, UC is classified as inactive, mild, moderate, severe or fulminant.  
Table 2: Inclusion and Exclusion Criteria for Recipient Patients 
Inclusion Exclusion 
1. All patients will be over the age of 
18 and be able to provide 
informed consent. 
2. All patients will have a 
histological diagnosis of UC.  
3. All patients will have a Mayo 
score of 6-12 indicating moderate-
to-severe disease severity4. 
4. All patients will have refractory 
disease while on standard doses of 
5-ASA. 
5. All patients will have been on a 
stable dose of 5-ASA for 2-4 
weeks.  
1. Any patients with severe systemic 
illness.  
2. Any patients who have used 
antibiotics or probiotics within 4 
weeks of starting trial.  
3. Patients with any concurrent 
infection. 
4. Any patients who are pregnant.  
5. Patients who have received any 
immune modulating therapies.  
6. Patients who have received any 
biologic medications.   
7. Patients who have previously 
received any corticosteroids.  
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8. Patients who have an undetectable 
thiopurine methyltransferase 
genotype.  
9. Patients who are receiving 
treatment for tuberculosis.  
 
The estimated sample size will be 84 patients with active UC using sample size 
calculations that assume a 70% remission rate in the FMT arm and 46% remission rate in 
the placebo arm given 90% power and 5% significance.  
Treatment  
The eligible study population will be randomized 1:1 using computer generated 
randomization based on a complete list of patients from all of the participating medical 
centers. Group A will include 50% of the recruited patients and they will receive FMT, 6-
mercaptopurine (50mg PO QD) and prednisone taper (see Table 3). Group B will include 
50% of the recruited patients and they will receive placebo, 6-mercaptopurine (50mg PO 
QD) and prednisone taper (see Table 3).  
 Table 3: Prednisone Taper Regimen 
Number of Days Doses 
7 
7 
7 
7 
7 
40 mg 
30 mg 
20 mg  
10 mg 
5 mg 
 
FMT donor screening, collection and processing will be performed per the Open 
Biome protocol for lower delivery microbiota preparation. Patients from both groups will 
undergo colonoscopies with biopsies on the first day they initiate their 6-MP regimen to 
assess baseline disease prior to starting therapy. At this time, Group A will receive 
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250mL of FMT via the colonoscopy according to the protocols established at each 
institution. Group B will receive 250mL of water via colonoscopy following the same 
methods in Table 2. Group A will then then take 6-mercaptopurine 50mg PO QD, 
Prednisone taper and Open Biome FMT capsule G3 (10 capsules once a week) for 8 
weeks. Group B will take 6-mercaptopurine 50mg PO QD, Prednisone taper and placebo 
capsules (10 capsules once a week) for 8 weeks.  
Study variables and measures 
The primary outcome will be clinical remission of UC by week 8, defined as a Mayo 
score of <3 and endoscopic Mayo score of =010,31. Secondary outcome will be fecal 
calprotectin value of <50 which indicates absence of significant intestinal inflammation. 
Additional secondary outcomes will be improvement in Inflammatory Bowel Disease 
Questionnaire (IBDQ) score and the serum inflammatory biomarkers C-reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR). 
Recruitment 
Patients with moderate to severe UC who meet the inclusion and exclusion criteria will 
be recruited from the outpatient gastroenterology clinics of Boston Medical Center, 
Brigham and Women’s Hospital, Lahey Medical Center, Tufts Medical Center, Beth 
Israel Deaconess Medical Center and Massachusetts General Hospital. Each institution 
will be responsible for generating a list of eligible patients who receive gastroenterology 
care at their facility. Candidates will initially be informed of the study one week prior to a 
scheduled outpatient visit with their gastroenterologist. At the time of the visit, the 
investigators will meet with the patients to provide further details about the trial including 
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risks and benefits. Individuals who choose to be enrolled will sign a consent form to be 
registered for the study. 
Data collection 
Prior to starting therapy, each patient will undergo a complete physical exam and medical 
history. A stool and blood sample will be collected and analyzed for specific markers 
detailed in Table 4. Additionally, patients will take an Inflammatory Bowel Disease 
Questionnaire survey to obtain a baseline score.  
Table 4: Baseline Stool and Blood Testing 
Stool Studies Blood Studies 
1. Fecal Calprotectin 
2. Clostridium difficile 
3. Salmonella 
4. Shigella 
5. Campylobacter 
6. E. Coli O157 
7. Ova and Parasites 
1. Complete Blood Count 
2. ESR 
3. CRP 
4. Thiopurine Methyltransferase 
Genotype 
5. Human Immunodeficiency Virus 
IgG (types 1 and 2) 
6. Quantiferon-TB Gold in-tube test 
7. Hepatitis A IgG and IgM 
8. Hepatitis B surface antigen, 
surface antibody, and core 
antibody 
9. Hepatitis C IgG and IgM. 
 
Patients will receive a phone call at weeks 1, 2, and 5 after the start of treatment 
to assess for adverse events (see Appendix 1). 
Patients will have a gastroenterology clinic visit at week 4 for a complete physical 
exam, and to provide stool and blood samples. They will also complete IBDQ at this 
visit. Patients will have colonoscopies with biopsies performed at week 8 to 
endoscopically evaluate disease response to treatment. At this time, they will again 
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undergo a complete physical exam and provide stool and blood samples. Patients will 
have a follow up clinic visit at week 12 (4 weeks after therapy completion) for a final 
physical exam, stool and blood collection and IBDQ.  
Data analysis 
A Pearson’s chi squared test will be used to analyze the primary outcome: patients in 
clinical remission at the end of the study. Absolute risk and relative risk for remission 
will be calculated between groups as well as number needed to treat. Quantitative 
variables such as Mayo score, fecal calprotectin, IBDQ score, ESR and CRP will be 
statistically analyzed using SAS 9.3 (Cary, NC). Appropriate means, standard deviations, 
and ranges will be calculated. Continuous data will be analyzed using student’s t-tests 
and linear regression. Descriptive statistics will be used to characterize patients by 
demographic features such as age and ethnicity. Pearson’s correlation coefficient will be 
use to assess correlations between gender, smoking status and extent of disease. 
Multivariate analysis, specifically multiple logistic regression analysis, will be used to 
adjust for possible confounders.  Stratified analysis will be used to control the effect of 
any baseline factors that are determined to be confounders.  
Timeline and resources 
Table 5: Study Timeline 
Fall 2016 IRB Submission and Approval 
January 2017-January 2018 Patient Recruitment  
Treatment Intervention  
Spring 2018 Data Analysis 
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Manuscript Submitted for Peer Review 
 
The primary investigator and co-investigators at each medical center will perform project 
oversight, data collection and data entry. A statistician will perform analysis of the data.  
Institutional Review Board 
The protocol of the study will be submitted for full IRB review to the Boston University 
Medical Campus IRB under INSPIR II criteria, and to the corresponding IRBs of the 
participating institutions. 
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CONCLUSION 
Discussion 
This study does have notable limitations. First, the recruited subjects will all likely be 
from Northeast region of the United States. This would limit the generalizability of the 
study to other parts of the country given the gut flora from donors and patients would be 
from one geographical area. Secondly, because the study calls for individuals with a 
specific disease severity, it will not be generalizable to those who do not fit the targeted 
category. Furthermore, the sample size of the study is relatively small. Finally, there are 
no studies that have evaluated the most efficacious mode of delivery and dose of FMT; 
therefore, these factors may need to be adjusted to have increased response rates.  
 Additionally, the study does have anticipated obstacles. The treatment plan 
requires adherence to large numbers of oral medications as well as close follow up with 
frequent clinic visits and telephone calls. This can be very time consuming and 
unfavorable to subjects which may result in participants exiting the study.  If this does 
prove to be a significant barrier, it will be important to simplify the treatment regimen 
and educate subjects on the importance of close follow-up.   
Summary 
The step up approach for the medical management of ulcerative colitis has been widely 
accepted by gastroenterologists. However current therapies rely on targeting the immune 
system from the side of the host, rather than the intestinal triggers of inflammation. 
Advancing research has revealed that intestinal dysbiosis may also contribute to UC and 
this can be corrected to restore a more natural gut microbiome with the use of FMT. 
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Using a treatment modality that addresses both immune dysregulation towards 
commensal bacteria and dysbiosis may be a beneficial addition to the step up approach.  
Research has showed that FMT has the potential to be an efficacious adjuvant 
treatment for patients with UC. However, current FMT studies have inconsistent 
combination treatment regimens in the subjects. Moreover, sub-analysis of these studies 
have shown increased remission in patients taking FMT and immunomodulating 
therapies compared to those taking other medications, but this has not been specifically 
investigated.   
The proposed study will use a combination of FMT, 6-MP and corticosteroids to 
evaluate if this is an efficacious regimen for inducing remission in patients with moderate 
to severe UC. This project will help to identify if correcting dysbiosis and modulating the 
immune system is beneficial for patients suffering from acute disease flairs. Furthermore, 
this study can provide information that would increase options for both UC patients and 
gastroenterologists when choosing treatment plans. 
Clinical and/or public health significance 
Patients who suffer from UC that is refractory to medical management commonly require 
surgical intervention to prevent serious complications. Although curative, a total 
colectomy is an invasive, life changing intervention. By identifying if FMT is an 
effective adjuvant, an additional component can be added to the step up approach for 
managing UC. Ultimately, this could prolong or eliminate the necessity for surgery. The 
goal is to provide healthcare providers and patients with another effective regimen to 
medically manage such a complicated illness.  
 27 
APPENDIX 
Appendix 1: 
Phone Call Survey 
1. Have you been experiencing bloating or flatulence?   Yes No 
2. Have been experiencing abdominal pain?    Yes No 
3. Have you been experiencing diarrhea?    Yes No 
4. Have you been experiencing hematochezia?    Yes No 
5. Have you been experiencing fatigue?     Yes No 
6. Have you been experiencing fevers ?     Yes No 
7. Have you required any trips to the emergency department or to  
your primary care provider?      Yes No 
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